ABLYNX OUTLINES NEXT STEPS FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS
October 20, 2016 01:05 ET
|
Ablynx
AbbVie has decided at this time not to exercise its right to opt-in and license vobarilizumab in RA
Additional analysis of the Phase IIb RA studies of vobarilizumab further demonstrate its...
ABLYNX ANNOUNCES SECOND EXTENSION OF ITS ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC.
October 12, 2016 01:04 ET
|
Ablynx
GHENT, Belgium, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced a second extension of its research collaboration with a subsidiary of Merck & Co.,...
FMR LLC ANNOUNCE 9.22% SHAREHOLDING IN ABLYNX
October 11, 2016 01:05 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2...
ABLYNX INITIATES A PHASE III FOLLOW-UP STUDY OF ITS FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, FOR THE TREATMENT OF ACQUIRED TTP
October 10, 2016 01:15 ET
|
Ablynx
To evaluate the long-term safety and efficacy of caplacizumab
To evaluate the safety and efficacy of repeated treatment with caplacizumab
To characterise the severity and long term impact...
ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, MAY HAVE THE POTENTIAL TO REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH ACQUIRED TTP
September 29, 2016 01:05 ET
|
Ablynx
GHENT, Belgium, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] announced that it will today present additional data from post-hoc analyses of the Phase II TITAN study...
ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC.
September 15, 2016 01:07 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...
Ablynx Receives Transparency Notification From GAM Holding AG, GAM International Management Limited and Taube Hodson Stonex Partners LLP
September 06, 2016 01:19 ET
|
Ablynx
GHENT, Belgium, Sept. 6, 2016 (GLOBE NEWSWIRE) --
REGULATED INFORMATION
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...
ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE
August 25, 2016 01:10 ET
|
Ablynx
REGULATED INFORMATION
Very important clinical pipeline developments and a successful financing
Conference call and webcast today at 4pm CET/10am ET
GHENT, Belgium, Aug. 25, 2016 (GLOBE...
ABLYNX WILL ANNOUNCE ITS 2016 HALF YEAR RESULTS WITH WEBCAST ON 25 AUGUST 2016
August 17, 2016 01:09 ET
|
Ablynx
GHENT, Belgium, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will report its 2016 half year financial results and year-to-date business update on Thursday 25 August...
ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM ADRIANUS VAN HERK ANDVAN HERK INVESTMENTS B.V.
August 12, 2016 01:06 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Aug. 12, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2...